Azitra granted new U.S. patent protecting ATR-12 program

Azitra (AZTR) announced the issuance of a new U.S. patent protecting ATR-12, the company’s lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment for Netherton syndrome, a chronic and potentially fatal skin disease that is estimated to affect approximately 20,000 patients globally. The patent covers microbes that secrete one or more domains of the lympho-epithelial Kazal-type-related inhibitor protein and methods of using these microbes to treat skin diseases, including Netherton’s Syndrome.